

Formulation and Characterization of Transdermal Patch Containing Eucalyptus, Curcumin and Ginger Oils with its In-vitro Permeability Study Using Goat Skin and GC-MS Analysis

Gaurav Lokhande ¹, Amol Sherikar ^{1*}, John Disouza ¹

¹Department of Quality Assurance, SWVSM's Tatyasaheb Kore College of Pharmacy, Warananagar, 416 113, Maharashtra, India.

*Corresponding author: assherikar.tkcp@gmail.com

Abstract

The present research has been carried out to formulate the transdermal patch containing medicinal oils like eucalyptus, curcumin, and ginger with its characterization and in-vitro permeability checking by GC-MS analysis. Three formulations (F1, F2, and F3) of transdermal patches containing different concentrations of oils were prepared. The patches were evaluated for thickness, weight uniformity, percentage moisture content, and percentage moisture uptake. The average thickness was found to be 0.434, 0.433, and 0.438 mm for F1, F2, and F3 respectively. 0.1876, 0.1861, and 0.1866 gm weight uniformity were observed for F1, F2, and F3 respectively. The moisture content for F1 was 3.96 %, for F2 was 2.48 % and for F3 was 3.67 %. The moisture uptake for F1 was 5.68 %, for F2 was 4.32 % and for F3 was 4.82 %. The F2 formulation produced optimum results, so it is better than F1 and F3. The in-vitro permeation of oils from the transdermal patch was checked by Franz diffusion cell using goat skin as a semi-permeable membrane. The transferred sample was collected and investigated by chemical identification tests at time intervals of 1, 2, 3, 4, and 5 hours for the presence of active chemical constituents. The GC-MS analysis showed the presence of active chemical moieties which transferred through the

goatskin including D-limonene, (+)-4-carene, Fenchone, linalool, endo-borne, citronellal, 2,6-octadienal, 3,7-dimethyl-, (Z)-, longifolene, caryophyllene, carotol, diethyl phthalate, etc. The above research proves our approach to formulation and delivery of polyherbal oils in a single transdermal patch which may open the door for delivery of formulation containing herbal oils through the skin.

Keywords: Transdermal patch, In-vitro permeability, GC-MS, Franz diffusion cell, D-Limonene, Caryophyllene.

Introduction

The transdermal drug delivery system (TDDS) has an essential component of emerging technologies for the release of medications (1). A TDDS applies a reasonably prescribed amount of the medicine to the inside of a patch; that is applied on the local site of the skin for an incredibly longer effect. The medication reaches the systemic circulation via the skin by diffusion mechanism (2). From the patch a balanced concentration of drug diffuses into the bloodstream for an extended period, ensuring a constant concentration of drug in the systemic circulation. This not only improves the drug effectiveness and safety, but it also improves patient fulfilment and overall gives therapeutic benefit (3). TDDS has some benefits such as

Formulation and characterization of transdermal patch containing eucalyptus, curcumin and ginger oils with its in-vitro permeability study using goat skin and GC-MS analysis

being less invasive or non-invasive, avoiding first-pass metabolism, being easy to apply, not requiring expert personnel, and having the potential to reduce the rate of administration (4).

Several transdermal therapeutic systems have been developed for topical administration to regulate therapeutic drug delivery. There are several topical ayurvedic drugs formulated and reported as an herbal patches (5-8). There are different types of transdermal patches reported like Drug-in adhesive with a single layer type of patch, Drug-in adhesive with multiple layers, Matrix type of patch, etc (9). Eucalyptus oil is obtained from *Eucalyptus* spp. and has a variety of biological activities like anti-microbial, anti-fungal, cardinal, insecticidal, herbicidal, anti-inflammatory, and analgesic, etc (10-11). The chemical moieties responsible for all the above biological activities present in eucalyptus oil are 1, 8-cineole, piperitone, citronellal, citronellol, linalool, *p*-cymene, *a*-phellandrene, *a*-pinene, *a*-terpineol, limonene, alloocimene, *g*-terpinene, geranyl acetate, spathulenol, *a*-thujene, etc (10).

Curcumin essential oil is obtained from *Curcuma longa* and reported many biological activities such as antihyperlipidemic (12), antidiabetic and hypoglycaemic (14), antiobesity (15), antioxidant (14-16), neuroprotective (17-19), antiplatelet and antithrombosis (20-21), cytotoxic (22-23), anti-inflammatory (19, 24), antiarthritic and joint-protective (25), hepatoprotective and antihepatotoxic (26), antiatherosclerotic (27), hypothermic (28), anxiolytic (28), anticonvulsant (28), spasmolytic (29), antimutagenic (30), sedative and anesthetic (28, 31), antivenom (32), antibacterial (33), antifungal (34, 35), insecticidal (36, 37), mosquitocidal (38), phytotoxic (39), antitumor (40), hypoglycemic (41), larvicidal (42) etc. The above reported biological activities are because of presence of phytochemical constituents such as *a*-turmerone, *b*-turmerone, *a*-curcumene, zingiberene, curcumenol, xanthorrhizol, curcumol, germacrone, curdione, curzerenone, curzerene, 8,9-dehydro-9-formyl-

cycloisolongifolene, *b*-caryophyllene, (E)-*b*-farnesene, *b*-elemenone, *b*-elemene, *b*-pinene, camphor, 1,8-cineole, piperitenone, *b*-myrcene (43) etc.

Ginger oil is obtained from dried rhizomes of the *Zingiber officinale* having a variety of reported biological activities like antioxidant (44), anti-tumour (45-46), anti-inflammatory and analgesic activity (47), anti-microbial activity (48), hepato-protective activity (49-50), etc. All above reported biological activities are because of the active phytoconstituents present and reported in ginger oil and which are paradol, shogoal, zingerone, zerumbone, 1-dehydro-(10) gingerdione, gingerol, gingerenone A, etc (51).

By considering all the above information from the literature, we are reporting here an attempt to formulation and characterization of a transdermal patch containing eucalyptus, curcumin, and ginger oils for treating inflammation and pain. The in-vitro permeability study by using goat skin and GC-MS analysis was carried out for the formulated transdermal patch.

Materials and Methods

Collection of volatile oils (*Eucalyptus*, *Curcumin* and *Ginger*), chemicals, polymers etc.

The oils were procured from a local ayurvedic drug supplier from Kolhapur (Bawadekar ayurvedic shop). The oil samples were then checked for their purity by organoleptic tests (physical state, color, odor, etc), density, and refractive index. The collected oil samples were stored in an airtight amber-colored container at room temperature. HPMC K4M, EC 7 cps, PVP K30, and propylene glycol (PG) were procured from Sigma-Aldrich. Synthetic PVA was procured from Loba Chemie Pvt. Ltd., Mumbai, India. PEG-4000 was obtained as a gift sample from BASF Mumbai, India. All other materials and chemicals used were of either pharmaceutical or analytical grade.

Formulation of herbal transdermal patches

The herbal transdermal patches were prepared by different methods.

Method 1

Transdermal patches containing volatile oils were prepared using 4 gm of polymer PVA as a backing membrane and as a dispersion polymer. The patches were formulated by first preparing PVA as a backing membrane and then dispersing HPMC polymer in different concentrations in water and ethanol. The backing membrane was prepared and allowed to dry for 24 hours at room temperature. 2 ml of curcumin oil and HPMC were mixed with the appropriate solvent for 1 hour, then 1gm of PEG and plasticizer PEG 4000 were added and the stirring was continued for another hour. Then using a pipette, 5 ml of a dispersion-containing mixture was poured over the previously prepared backing layer of PVA. By placing an inverted funnel over the glass Petri plate, the solvent was allowed to evaporate at room temp. The film was collected and analyzed 24 hrs after drying at room temperature.

Method 2

PVP (1000 mg) and EC (1000 mg) was used as the skeletal type of polymeric material. PG as a penetration enhancer and PEG-4000

was used as a plasticizer. The polymer PVA and EC were weighted in required ratios and mixed into a 50 ml solution containing methanol and distilled water (1:1) ratio. Stirred the mixture over a hot water bath until dissolved, after the mixture was cooled down to 25 °C the volatile was added. After that, PG (0.5 ml), was added, and the mixture was then poured into a glass Petri dish and dried at room temperature for 24 hrs. The Petri dish was left and placed at room temperature for one day. The patch was obtained intact by slowly lifting from the Petri dish and collected, and stored until further use.

Method 3

PVA (1000 mg) and PVP (1000 mg) and drug were weighted in requisite ratios and mixed in 10 ml distilled water. Stirred the mixture over a hot water bath until it dissolved. After that mixture was cooled down to 25 °C, added glycerol (0.5ml), PG (0.5 ml), and pressure-sensitive adhesive such as Di-n-butyl phthalate (2 ml). PEG-4000 was used as a plasticizer. The solution was mixed by using a mechanical stirrer at 600 to 800 rpm for 20 min. under occluded condition, and then the mixture was cast on the Petri dish and kept at room temperature for 24 hrs. In table 1 the different ingredients with their quantity used in formulation F1, F2, and F3 are given.

Table 1: Showing different polymers and oils used for preparation of transdermal patches

| F1 (Method 1) | | F2 (Method 2) | | F3 (Method 3) | |
|--------------------------------|----------|--------------------------------|----------|--------------------------------|----------|
| Name of Ingredient | Quantity | Name of Ingredient | Quantity | Name of Ingredient | Quantity |
| PVA | 1000 mg | EC | 1000 mg | PVP | 1000 mg |
| HPMC | 1000 mg | PVP | 1000 mg | PVA | 1000 mg |
| PG | 0.5 ml | PEG-4000 | 1000 mg | PEG-4000 | 1500 mg |
| Glycerol | 0.5 ml | PG | 0.5 ml | Glycerol | 0.5 ml |
| Dist. Water : Ethanol (1:1) | 50 ml | Dist. water: methanol (1:1) | 50 ml | PG | 0.5 ml |
| Curcumin oil | 1 ml | Glycerol | 0.5 ml | Di-n-butyl phthalate | 2 ml |
| Eucalyptus oil | 1 ml | Curcumin oil | 1 ml | Dist. water: methanol (1:1) | 50 ml |
| Ginger oil | 1 ml | Eucalyptus oil | 1 ml | Curcumin oil | 1 ml |
| | | Ginger oil | 1 ml | Eucalyptus oil | 1 ml |
| | | | | Ginger oil | 1 ml |

F1 = formulation 1, F2= formulation 2 and F3 = formulation 3

Formulation and characterization of transdermal patch containing eucalyptus, curcumin and ginger oils with its in-vitro permeability study using goat skin and GC-MS analysis

Evaluation of patches (53, 56, 57)

The patch thickness

The thickness of prepared drug-loaded patches was measured at different points by using a vernier calliper and determined the average thickness (56-57).

Weight uniformity

Specified areas of prepared patches were cut into different parts and weighed on a digital balance, and the average weight was calculated (56).

Percentage moisture content

The prepared films were weighed individually and kept in desiccators with fused calcium chloride at room temp for 24 hrs. After 24 hrs the film was reweighed and determined percentage moisture content (53, 56).

Percentage moisture uptake

The weighted films were kept in desiccators at room temp for 24 hours in a saturated potassium chloride solution. After 24 hrs the films were reweighed and determined the percentage of moisture uptake (53).

In-vitro oil constituents release study (Permeation study) by Franz diffusion cell method

Preparation of goat skin

The goatskin was used as semi-permeable membrane, collected from local slotter house nearby college campus. Freshly excised skin was placed for 1 min in distilled water maintained at 55°C to remove fats and subcutaneous tissues. The skin was washed with fresh distilled water and dipped in a phosphate buffer at pH 7.4 for 5 min. The excised skin was carefully checked visually for integrity. Any damaged skin was rejected. The prepared skin was wrapped in aluminium foil, stored at -20°C, and used within 2 weeks of storage (58-59).

Permeation Experiment

The in-vitro oil constituents release (permeation) study was carried out by the Franz diffusion cell method. Franz diffusion cells consist of two compartments i.e. donor and acceptor with an outer jacket. The outer jacket was placed in a water bath at 37 °C to provide a temperature of 32°C±1°C in the receptor compartment. The goatskin was used as a semi-permeable membrane. The skin was allowed to maintain a temperature of 32 °C by placing the skin in a phosphate buffer of pH 7.4 for 1 hour. The receptor compartment was filled with a phosphate buffer pH 7.4.

The goatskin was mounted between the donor and the receptor compartments in such a way that the stratum corneum was facing toward the donor compartment. A circular piece of the patch was cut from a larger patch with the help of a cutter. A circular patch was placed on the skin with the releasing side facing toward the mounted skin. The receptor fluid was continuously stirred at a speed of 120 rpm with magnetic bars on a magnetic stirrer (REMI equipment Pvt Ltd., India) to provide sink conditions. At predetermined intervals of 1, 2, 3, 4, and 6 hrs, 1 mL of receptor fluid was withdrawn from the sampling port with the help of a long needle syringe.

The receptor fluid was replaced with fresh phosphate buffer. Care was taken during sampling to avoid any bubble formation in the receptor compartment, because trapped air may reduce the permeation area. In case of air entrapment, the Franz diffusion cell was tilted to remove the trapped air through the sampling port. The donor compartment was covered with aluminium foil (59).

GC-MS study

The GC-MS study was conducted in the common facilities center (CFC), Shivaji University, Kolhapur. The analysis was carried out on a Shimadzu instrument (model TQ8050). The sample collected at 6 hrs time interval

of formulation F3 was injected into the gas chromatography. The method setting and programming details are given in table 2.

Table 2: Showing Gas Chromatographic programming and method details (60).

| | |
|-----------------------------------|--|
| Column oven Temperature programme | 50 hold for 2 minutes at 10 °C, 200 hold for 5 minutes, 250 hold for 5 minutes, 275 holds for 5 minutes. |
| Injection temperature | 25 °C |
| Injection mode | Splitters |
| Carrier gas | Helium (He) |
| Column flow | 1 ml/min. |
| Sample volume | 1µl |

The separated compounds in the form of different peaks at different retention times (Rt) were transferred into the MS. The MS was carried out by setting of programming parameters given in table 3.

Table 3: MS programming parameters [60]

| | |
|-----------------------|-----------|
| In source temperature | 24 °C |
| Interface temp | 25 °C |
| Solvent cut time | 5.8 min. |
| m/z range | 45 to 650 |
| Detector voltage | 0.76 |

The ionization, filtration and detection were carried out and the fragments of different ions were recorded.

Result and Discussion

Physicochemical characterization of procured oils

Organoleptic tests

The organoleptic tests for eucalyptus, curcumin, and ginger oils resemble the official monographs.

Density

The relative density is a basic physical

property of an oil/substance that can be used to characterise it. The density is the ratio of mass of a substance to volume of substance at given temperature. The relative densities for all three oils i.e. eucalyptus, ginger, and curcumin were 0.866g/ml, 0.970g/ml, and 0.871/ml respectively. The standard values for the same are 0.865g/ml, 0.960 mg/ml and 0.871 g/ml respectively at room temperature.

Refractive Index

The Refractive indices of volatile oils were determined by using Abbe's refractometer. The refractive index is one of the physicochemical properties of the substance. The refractive index (n) of a substance with reference to air is the ratio of the sine of the angle of incidence to the sine of the angle of refraction of a beam of light passing from air into the substance. It is mostly applied for identify a particular substance, confirm its purity, or measure its concentration. Generally it is used to measure the concentration of a solute in an aqueous solution. It can be used also in determination of drug concentration in pharmaceutical industry (52). The refractive indices of Eucalyptus, Ginger, and Curcumin oil were 1.461, 1.400, and 1.450 respectively, and the standard refractive index is 1.450, 1.485, and 1.500 respectively.

Formulation and evaluation of herbal transdermal patches

The patches were prepared by using combinations of polymers such as hydroxyl propyl methyl cellulose K4M (HPMC), ethyl cellulose 7 cps (EC), synthetic polyvinyl alcohol (PVA), polyvinyl pyrrolidone K30 (PVP), and polyethylene glycol 4000 (PEG-4000). The formulated patches get softened and extend because of plasticizers. The formulation was subjected to a physical examination; films appeared slightly translucent suggesting that the transdermal patch containing oils was successfully prepared. Further, the patches were evaluated for thickness, weight uniformity, moisture content, and moisture uptake, and the results are tabulated in Table 1.

Formulation and characterization of transdermal patch containing eucalyptus, curcumin and ginger oils with its in-vitro permeability study using goat skin and GC-MS analysis

Table 1: Showing result of thickness, weight uniformity, moisture content, moisture uptake of prepared transdermal patches

| Name of formulation | Average thickness (mm) | Weight uniformity (gm) | Moisture content (%) | Moisture uptake (%) |
|---------------------|------------------------|------------------------|----------------------|---------------------|
| F1 | 0.434 | 0.1876 | 3.96 | 5.68 |
| F2 | 0.433 | 0.1861 | 2.48 | 4.32 |
| F3 | 0.438 | 0.1866 | 3.67 | 4.82 |

Each patch's thickness was measured with a vernier calliper at different points on the patch, the average thickness for F1, F2 and F3 was 0.434, 0.433 and 0.438 mm respectively. All the patches were found to be having uniform thickness. The average weight for F1, F2 and F3 was 0.1876, 0.1861 and 0.1866 gm respectively. It was found that the weights were uniform for all prepared formulations and the weight variation was within acceptable range. The moisture content for F1, F2 and F3 was 3.96, 2.48 and 3.67% respectively. The moisture uptake for F1, F2 and F3 was 5.68, 4.32 and 4.82 respectively. The moisture content and moisture uptake studies provide information regarding stability of the formulations. For maximum stability the moisture content and moisture uptake of transdermal patch should be minimum (53-55). In this case formulation F2 showed optimum results so it is better than F1 and F3. The results obtained were promising and the prepared transdermal patches were stable.

Permeation study

The permeation studies of the transdermal patches helps to predict the in vivo absorption of the drug. The permeation studies were performed by Franz diffusion cell method using goat skin as a semi-permeable membrane. The drug samples were collected

at an interval of 1,2,3,4 and 6 hrs. The GC-MS study was carried out for the presence of different chemical moieties in the receptor compartment.

GC-MS analysis

The GC-MS analysis of batch F3, for 6 hrs receptor sample was carried out. The GC spectra are shown in figure 1 showing different peaks at different retention times (Rt). The detailed chromatographic separation data with retention time (Rt), initial time (It), final time (Ft), peak area, % area, and name of chemical moiety representing it is given in table no. 2. The major components were D-limonene (14.95), (+)-4-carene (2.20), fenchone (1.71), linalool (1.67), acetaldehyde (9.27), camphor (6.09), endo-borneol (1.39), L-.alpha.-terpineol (4.80), citronellal (3.64), 2,6-octadienal,3,7-dimethyl-, (Z)- (1.59), isobornyl acetate (4.44), geranyl acetate (8.55), 2H-2,4a-Methanonaphthalene,1,3,4,5,6,7-hex (1.91), longifolene (2.87), caryophyllene (3.94).




Fig 1: Gas chromatographic spectra of F3 batch (6 hrs time interval samples)

Table 2: Showing time (Rt), initial time (It), final time (Ft), peak area, % area, and name of chemical moiety separated by GC.

| Peak no. | Rt | It | Ft | Area | % Area | Name of chemical moiety separated |
|----------|-------|-------|-------|-----------|--------|-----------------------------------|
| 1 | 7.999 | 7.835 | 8.135 | 196633623 | 14.95 | D-Limonene |
| 2 | 8.985 | 8.890 | 9.050 | 28894459 | 2.20 | (+)-4-Carene |
| 3 | 9.110 | 9.080 | 9.200 | 22457757 | 1.71 | Fenchone |
| 4 | 9.316 | 9.255 | 9.355 | 21973067 | 1.67 | Linalool |

| | | | | | | |
|----|--------|--------|--------|-----------|------|--|
| 5 | 9.467 | 9.355 | 9.515 | 121845201 | 9.27 | Acetaldehyde |
| 6 | 10.158 | 10.070 | 10.260 | 80075561 | 6.09 | Camphor |
| 7 | 10.336 | 10.280 | 10.385 | 12830938 | 0.98 | (1R,2R,5S)-5-Methyl-2-(prop-1-en-2-yl)cyclo |
| 8 | 10.464 | 10.410 | 10.530 | 18235358 | 1.39 | endo-Borneol |
| 9 | 10.958 | 10.875 | 11.085 | 63118662 | 4.80 | L-.alpha.-Terpineol |
| 10 | 11.410 | 11.295 | 11.505 | 47805732 | 3.64 | Citronellal |
| 11 | 11.550 | 11.510 | 11.600 | 20919610 | 1.59 | 2,6-Octadienal,3,7-dimethyl-,(Z)- |
| 12 | 12.356 | 12.270 | 12.480 | 58390518 | 4.44 | Isobornyl acetate |
| 13 | 12.837 | 12.760 | 12.870 | 8747719 | 0.67 | (2R,2'S,5S,5'S)-2,5'-Dimethyl-5-(prop-1-en-2- |
| 14 | 13.118 | 13.065 | 13.155 | 17261624 | 1.31 | 6-Octen-1-ol,3,7-dimethyl-,propanoate |
| 15 | 13.575 | 13.470 | 13.650 | 112483497 | 8.55 | Geranyl acetate |
| 16 | 13.823 | 13.785 | 13.860 | 8893979 | 0.68 | Cyclohexane |
| 17 | 13.980 | 13.935 | 14.025 | 25137325 | 1.91 | 2H-2,4a-Methanonaphthalene, 1,3,4,5,6,7-hex |
| 18 | 14.221 | 14.160 | 14.270 | 37786059 | 2.87 | Longifolene |
| 19 | 14.336 | 14.270 | 14.270 | 51780013 | 3.94 | Caryophyllene |
| 20 | 14.393 | 14.360 | 14.430 | 8294650 | 0.63 | Bicyclo[3.1.1]heptane,6-methyl-2-methylene- |
| 21 | 14.814 | 14.755 | 14.855 | 18496067 | 1.41 | 1,4,7,-Cycloundecatriene, 1,5,9,9-tetramethyl- |
| 22 | 15.016 | 14.955 | 15.055 | 9930168 | 0.76 | Carotol |
| 23 | 15.359 | 15.280 | 15.415 | 19665565 | 1.50 | 2-Octen-1-ol,7-ethoxy-3,7-dimethyl-, (E)- |
| 24 | 15.577 | 15.490 | 15.625 | 32777390 | 1.50 | 2-Octen-1-ol,7-ethoxy-3,7-dimethyl-, (E)- |
| 25 | 16.473 | 16.380 | 16.505 | 47432263 | 3.61 | Diethyl Phthalate |
| 26 | 16.668 | 16.625 | 16.705 | 26235615 | 1.99 | Diethyl Phthalate |
| 27 | 16.863 | 16.820 | 16.895 | 26199705 | 1.99 | Diethyl Phthalate |

The GC-MS study confirmed the presence of various chemical moieties in transdermal patch which passes the semi permeable membrane (goat skin) and appears with different retention time as illustrated in figure 1. The mass spectrometer analyzes the compounds eluted at different retention times to identify the nature and structure of the compounds. The large compound fragments into small compounds giving rise to appearance of peaks at different m/z ratios. The MS fragmentation pattern of different separated compound in gas chromatography is given in supplementary material which is attached separately.

Conclusion

In conclusion, taken together the results showed that all the three formulations

i.e. F1, F2 and F3 were successfully formulated incorporating the combination of oils like eucalyptus, ginger and curcumin oil. All the formulations produced optimum results but formulation F2 showed minimum % of moisture content (2.48) and moisture uptake (4.32), so it is better than F1 and F3. This may be because all the three formulations were prepared by three different methods. The in-vitro permeation study revealed that the active chemical moieties were transferred into the hydro-alcoholic solution through semi-permeable membrane (goat skin) and which were detected and identified by GC-MS study. The above results are promising for further preparation of transdermal patches containing herbal drugs and oils in a combination for the treatment of various diseases like inflammation, pain, gout, rheumatoid arthritis and many more diseases where herbal drugs

Formulation and characterization of transdermal patch containing eucalyptus, curcumin and ginger oils with its in-vitro permeability study using goat skin and GC-MS analysis

and oils are applied externally.

Acknowledgements

The authors are thankful to the Management of Shree Warana Vibhag Shikshan Mandal's Tatyasaheb Kore College of Pharmacy, Warananagar for providing all necessary facilities to carry out this work.

Authors have declared no conflict of interest

References

1. Bathe, R., Kapoor, R. (2015). Transdermal drug delivery system, formulation, development and evaluation- An overview. *Int. j. biomed. adv. Res.*, 1(6):1-110.
2. Verma, G. (2017). Transdermal drug delivery system, advance development and evaluation. *Int. j. pharm. sci.*, 8(2):385-400. DOI: 10.13040/IJPSR.0975-8232.8(2).385-400.
3. Vijaya, N., Ravi Shankar, V. (2010). A brief about transdermal drug delivery system. *J. Pharm. Res.*, 3(11): 263-273.
4. Gore, S., Satpute, V., Gholve, S. (2017). A systemic review on transdermal patches. *Int. J. Pharm. Sci. Rev. Res.*, 45(2); 133-140.
5. Krishna, M., Savula, J. (2017). Formulation of herbal transdermal patches, *Int. J. Pharm. Res.*, 6(13): 365-374. DOI: 10.20959/wjpr201713-9667.
6. Suryani, W., Odesitti, M. (2015). Formulation and physical characterization of curcumin nanoparticle transdermal patch. *J. Pharm. Sci.*, 11(9): 217-221. DOI: <https://doi.org/10.22159/ijap.2019v11i6.34780>.
7. Samiullah Sayed Umar Jan. (2019). Formulation and evaluation of transdermal patches of pseudo-phedrine HCL. *Int. J. Appl. Pharm.*, 12(3): 121-127. <https://doi.org/10.22159/ijap.2020v12i3.37080>.
8. Lalit kumar, Shivani Verma. (2018). Advance drug delivery system for transdermal delivery of non-steroidal anti-inflammatory drugs. *Advance in Pharmaceutical Science*, 6(16): 121-130. doi:<https://doi.org/10.1155/2016/9130979>.
9. Audumbar Mali., Ritesh Bathe. (2015). An updated review on transdermal drug delivery systems. *Int. J. Adv. Sci.*, 1(6): 244-254.
10. Luiz Claudio Almeida Barbosa, Claudinei Andrade Filomeno, Robson Ricardo Teixeira. (2016). Chemical Variability and Biological Activities of *Eucalyptus* spp. Essential Oils. *Molecules*, 21: 1671-1703.
11. Jeane Silva, Worku Abebe, Sousa SM, Duarte VG, Machado MIL, Matos FJA. (2003). Analgesic and anti-inflammatory effects of essential oils of *Eucalyptus*. *J. Ethnopharmacol.*, 89(2-3):277-83. DOI: 10.1016/j.jep.2003.09.007.
12. Ling, J., Wei, B., Lv, G., Ji, H., Li, S. (2012). Anti-hyperlipidaemic and antioxidant effects of turmeric oil in hyperlipidaemic rats. *Food Chem.* 130: 229–235.
13. Nishiyama, T., Mae, T., Kishida, H., Tsukagawa, M., Mimaki, Y., Kuroda, M., Sashida, Y., Takahashi, K., Kawada, T., Nakagawa, K. (2005). Curcuminoids and sesquiterpenoids in turmeric (*Curcuma longa* L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. *J. Agric. Food Chem.* 53: 959–963.
14. Tsai SY, Huang SJ, Chyau CC, Tsai CH, Weng CC, Mau JL. (2011). Composition and antioxidant properties of essential oils from *Curcuma* rhizome. *Asian J. Arts Sci.* 2: 57–66.
15. Zhang, L., Yang, Z., Chen, F., Su, P., Chen, D., Pan, W., Fang, Y., Dong, C., Zheng, X., Du, Z. (2017). Composition and bioactivity assessment of essential oils of *Curcuma longa* L. collected in China. *Ind. Crops.*

- Prod., 109: 60–73.
16. Zhao, J., Zhang, JS, Yang, B., Lv, GP, Li, SP. (2010). Free radical scavenging activity and characterization of sesquiterpenoids in four species of *Curcuma* using a TLC bioautography assay and GC–MS analysis. *Molecules*, 15: 7547–7557.
 17. Dohare, P., Garg, P., Sharma, U., Jagannathan, NR, Ray, M. (2008). Neuroprotective efficacy and therapeutic window of *Curcuma* oil In rat embolic stroke model. *BMC Complement. Altern. Med.*, 8.
 18. Rathore, P., Dohare, P., Varma, S., Ray, A., Sharma, U., Jaganathanan, NR, Ray, M. (2008). *Curcuma* oil: Reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. *Neurochem. Res.*, 33: 1672–1682.
 19. Manhas, A., Khanna, V., Prakash, P., Goyal, D., Malasoni, R., Naqvi, A., Dwivedi, AK., Dikshit, M., Jagavelu, K. (2014). *Curcuma* oil reduces endothelial cell-mediated inflammation in postmyocardial ischemia/reperfusion in rats. *J. Cardiovasc. Pharmacol.*, 64: 228–236.
 20. Prakash, P., Misra, A., Surin, WR, Jain, M., Bhatta, RS, Pal, R., Raj, K., Barthwal, MK., Dikshit, M. (2011). Anti-platelet effects of *Curcuma* oil in experimental models of myocardial ischemia-reperfusion and thrombosis. *Thromb. Res.*, 127: 111–118.
 21. Lee, HS. (2006). Antiplatelet property of *Curcuma longa* L. rhizome-derived ar-turmerone. *Bioresour. Technol.*, 97: 1372–1376.
 22. Manosroi, J., Dhumtanom, P. Manosroi. (2006). A Anti-proliferative activity of essential oil extracted from Thai medicinal plants on KB and P388 cell lines. *Cancer Lett.*, 235: 114–120.
 23. Jayaprakasha, GK, Jena, BS, Negi, PS, Sakariah, KK. (2002). Evaluation of antioxidant activities and antimutagenicity of turmeric oil a by product from curcumin production. *Z Naturforsch.*, 57c: 828–835.
 24. Arora, R., Basu, N., Kapoor V., (1971). A. Anti-inflammatory studies on *Curcuma longa* (turmeric). *Indian J. Med. Res.*, 59: 1289–1295.
 25. Funk, JL, Frye, JB, Oyarzo, JN, Zhang, H., Barbara, N. (2010). Anti-arthritis effects and toxicity of the essential oils of turmeric (*Curcuma longa* L.), *J. Agric. Food Chem.*, 58: 842–849.
 26. Kiso, Y., Suzuki, Y., Watarable, N. (1983). Antihepatotoxic principles of *Curcuma longa* rhizomes. *Planta Med.*, 49: 185–187.
 27. Singh, V., Rana, M., Jain, M., Singh, N., Naqvi, A., Malasoni, R., Dwivedi, AK., Dikshit, M., Barthwal, MK. (2015). *Curcuma* oil attenuates accelerated atherosclerosis and macrophage foam-cell formation by modulating genes involved in plaque stability, lipid homeostasis and inflammation. *Br. J. Nutr.* 113: 100–113.
 28. Oyemitan, IA., Elusiyana, CA., Onifade, AO., Akanmu, MA., Oyedeji, AO., McDonald, AG. (2017). Neuropharmacological profile and chemical analysis of fresh rhizome essential oil of *Curcuma longa* (turmeric) cultivated in southwest Nigeria. *Toxicol. Rep.*, 4: 391–398.
 29. Shafreen, RB., Lubinska-Szczgel, M., Rozanska, A., Dymerski, T., Namiesnik, J., Katrich, E., Gorinstein, S. (2018). Human serum interactions with phenolic and aroma substances of Kaffir (*Citrus hystrix*) and Key lime (*Citrus aurantifolia*) juices. *J. Lumin.*, 201:115-122.
 30. Palasa, K., Scsikaran, B., Krishna, T.P., Krishnaswamy, K. (1992). Effect of turmeric on urinary mutagens in smokers. *Mutagenesis*, 7: 107–109.

Formulation and characterization of transdermal patch containing eucalyptus, curcumin and ginger oils with its in-vitro permeability study using goat skin and GC-MS analysis

31. Saccol, EM., Londero, H., Bressan, EP., Salbego, CA., Gressler, J., Silva, LT., Mourão, LVF., Oliveira, RHV., Llesuy, RB., Baldisserotto, SFB. (2017). Oxidative and biochemical responses in *Brycon amazonicus* anesthetized and sedated with *Myrcia sylvatica* (G. Mey.) DC. and *Curcuma longa* L. essential oils. *Vet. Anaesth. Analg.*, 44: 555–566.
32. Ferreira, LAF., Henriques, OB., Andreoni, AAS., Vital, GRF., Campos, MMC., Habermehl, GG., De Moraes, VLG. (1992). Antivenom and biological effects of ar-turmerone isolated from *Curcuma longa* (Zingiberaceae). *Toxicon*, 30:1211–1218.
33. Negi, PS., Jayaprakasha, GK., Jagan Mohan Rao L., Sakariah, K.K. (1999). Antibacterial activity of turmeric oil: A byproduct from curcumin manufacture. *J. Agric. Food Chem.*, 47: 4297–4300.
34. Behura, C., Ray, P., Rathi, CC., Mishra, RK., Ramachandraiah, OS., Charyulu, JK. (2000). Antifungal activity of essential oil of *Curcuma longa* against five rice pathogens in vitro. *J. Essent. Oil Bear. Plants*, 3: 79–84.
35. Apisariyakul, A., Vanittanakom, N., Buddhasukh, D. (1995). Antifungal activity of turmeric oil extracted from *Curcuma longa* (Zingiberaceae). *J. Ethnopharmacol.* 49: 163–169.
36. Fouad, HA., Da Camara CAG. (2017). Chemical composition and bioactivity of peel oils from *Citrus aurantiifolia* and *Citrus reticulata* and enantiomers of their major constituent against *Sitophilus zeamais* (Coleoptera: Curculionidae). *J. Stored Prod. Res.*, 73:30–36.
37. Roth, GN., Chandra, A., Nair, MG. (1998). Novel bioactivities of *Curcuma longa* constituents. *J. Nat. Prod.*, 61:542–545.
38. Tawatsin, A., Wratten, SD., Scott, RR., Thavara, U., Techadamrongsin, Y. (2001). Repellence of volatile oils from plants against three mosquito vectors. *J. Vector Ecol.*, 26:76–82.
39. Fagodia, SK., Singh, HP., Batish, DR., Kohli, RK. (2017). Phytotoxicity and cytotoxicity of *Citrus aurantiifolia* essential oil and its major constituents: Limonene and citral. *Ind. Crops Prod.*, 108: 708–715.
40. Chen, C., Chen, Y., Hsi, YT., Chang, CS., Huang, LF., Ho, CT., Way, TD., Kao, JY. (2013). Chemical constituents and anticancer activity of *Curcuma zedoaria* Roscoe essential oil against non-small cell lung carcinoma cells in vitro and in vivo. *J. Agric. Food Chem.*, 61: 11418–11427.
41. Handajani J Narissi DH. (2015). The effects of *Curcuma zedoaria* oil on high blood sugar level and gingivitis. *Dent. J.*, 69: 69–73.
42. Pitasawat, B., Champakaew, D., Choochote, W., Jitpakdi, A., Chaithong, U., Kanjanapothi, D., Rattanachanpichai, E., Tippawangkosol, P., Riyong, D., Tuetun, B. (2007). Aromatic plant-derived essential oil: An alternative larvicide for mosquito control. *Fitoterapia*, 78:205–210.
43. Noura, S. Dosoky, William N. Setzer. (2018). Chemical Composition and Biological Activities of Essential oils of *Curcuma* Species. *Nutrients*, 10:1196-1238.
44. Masuda, Y., Kikuzaki, H., Hisamoto, M., Nakatani, N. (2004). Antioxidant properties of gingerol related compounds from ginger. *Bio factors*, 21: 293-296.
45. Plengsuriyakarn, T., Viyanant, V., Eursitthichai, V., Tesana, S., Chaijaroenkul, W., Itharat, A., Na-Bangchang, K. (2012). Cytotoxicity and anti cancer activity of *Zingiber officinale* Roscoe against cholangiocarcinoma. *Asian Pac. J. Cancer Prev.*, 13: 4597-606.

46. Kim, HW., Oh DH., Jung, C., Kwon, DD., Lim, YC. (2011). Apoptotic Effects of 6-Gingerol in LNCaP Human Prostate Cancer Cells Soonchunhyang. *Med. Sci.*, 17: 75-79.
47. Young, HY., Luo, YL., Cheng, HY., Hsieh, WC., Liao, JC., Peng, WH. (2005). Analgesic and anti-inflammatory activities of [6]-gingerol. *J. Ethnopharm.*, 96: 207-310.
48. Park, M., Bae, J., Lee, DS. (2008). Antibacterial activity of [10]-gingerol and [12]-gingerol isolated from ginger rhizome against periodontal bacteria. *Phytother Res.*, 22: 1446-1449.
49. Alqasoumi, S., Yusufoglu, H., Farraj, A., Alam, A. (2011). Effect of 6-shogaol and 6-gingerol on Diclofenac Sodium Induced Liver Injury. *Int. J. Pharmacol.*, 7: 868-873.
50. Sabina, EP., Pragasam, SJ., Kumar, S., Rasool, M. (2011). 6-gingerol, an active ingredient of ginger, protects acetaminophen-induced hepatotoxicity in mice. *Zhong Xi Yi Jie He Xue Bao.*, 9: 1264-1269.
51. Arshad H. Rahmani, Fahad M A shabrmi, Salah M. Aly. (2014). Active ingredients of ginger as potential candidates in the prevention and treatment of diseases via modulation of biological activities. *Int. J. Physiol. Pathophysiol. Pharmacol.*, 6(2):125-136.
52. Fardad Koohyar. Refractive Index and Its Applications. (2013). *J. Thermodyn. Catal.*, 4:2.
53. Long Mo, Guijing Lu, Xiping Ou, Dongsheng Ouyang. (2022). Formulation and development of novel control release transdermal patches of carvedilol to improve bioavailability for the treatment of heart failure. *Saudi Journal of Biological Sciences*, 29:266-272.
54. K L Senthil Kumar, P D Gokulan, A Vasanthan, S Venkateswaran, H Santhosh, R Vinoth kumar, S Ragul. (2022). Preparation and evaluation of matrix type of transdermal patches containing anti-diabetic drug. *Indian Journal of Pharmacy and Pharmacology*, 9(1):29-34.
55. Kanabar Vishvesh B, Patel Vipul P, Doshi Sumit M. (2015). Formulation and evaluation of transdermal patch of Cefdinir with various polymers. *The Pharma Innovation Journal*, 4(6):74-77
56. Amit K. Vishwakarma, Om. P. Maurya. (2012). Formulation and evaluation of transdermal patch containing turmeric oil. *Int. J. Pharm. Pharm. Sci.*, 4(5):359-361.
57. Nirav S. Sheth, Rajan B. Mistry. (2011). Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. *J. Appl. Pharm. Sci.*, 01(03):96-101. www.japsonline.com.
58. Davaran, S., Rashidi, MR., Khandaghi, R., Hashemi, M. (2005). Development of a novel prolonged-release nicotine transdermal patch. *Pharmacol. Res.*, 51(3):233-237.
59. Muhammad Rouf Akram, Mahmood Ahmad, Asad Abrar, Rai Muhammad Sarfraz, Asif Mahmood. (2018). Formulation design and development of matrix diffusion controlled transdermal drug delivery of glimepiride. *Drug Des. Dev. Ther.*, 12: 349-364.
60. Velmurugan, G., Anand SP. (2017). GC-MS Analysis of Bioactive Compounds on Ethanolic Leaf Extract of *Phyllodium pulchellum* L. *Desv. International Journal of Pharmacognosy and Phytochemical Research*, 9(1):114-118.